ArticleNature methods2014
Reversible protein inactivation by optogenetic trapping in cells.
Article in Nature methods, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed.
- An ultralow-background far-red light-responsive optogenetic tool based on an engineered biliverdin-binding domain.Nature methods · 2026Article
- A single-component optogenetic toolkit for reversible visualization and programmable control of microtubule dynamics.Cell reports methods · 2026Article
- Light-induced spindle assembly through Aurora A clustering.EMBO reports · 2026Article
- Illuminating cancer therapy: The translational path of optogenetics.Bioactive materials · 2026Review
- The membrane transition strongly enhances biopolymer condensation through prewetting.Nature chemical biology · 2026Article
- Beyond The Nucleus: Translating Engineered Protein Localization To Chromatin Modifying Enzymes.Current opinion in biomedical engineering · 2026Article
- Review
- Remodeling synaptic connections via engineered neuron-astrocyte interactions.Nature communications · 2026Article
- Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026Review
- Cry2 prompts clock oscillation and temporomandibular joint homeostasis under mechanical loading.Bone & joint research · 2026Article
- Technological advances in visualizing and rewiring microtubules during plant development.Journal of experimental botany · 2025Review
- Tepsin and AP4 mediate transport from the trans-Golgi to the plant-like vacuole in toxoplasma.The Journal of cell biology · 2025Article
- A Rho GTPase-effector ensemble governs cell migration behavior.Nature communications · 2025Article
- Optogenetic enzymes: A deep dive into design and impact.Current opinion in structural biology · 2025Review
- Activation of NF-κB Signaling by Optogenetic Clustering of IKKα and β.Advanced biology · 2025Article
- Programmable solid-state condensates for spatiotemporal control of mammalian gene expression.Nature chemical biology · 2025Article
- Emerging roles of transcriptional condensates as temporal signal integrators.Nature reviews. Genetics · 2025Review
- Optogenetic storage and release of protein and mRNA in live cells and animals.Nature communications · 2025Article
- In vivo optogenetic manipulations of endogenous proteins reveal spatiotemporal roles of microtubule and kinesin in dendrite patterning.Science advances · 2024Article
- Actin-nucleation promoting factor N-WASP influences alpha-synuclein condensates and pathology.Cell death & disease · 2024Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a versatile platform to inactivate proteins in living cells using light, light-activated reversible inhibition by assembled trap (LARIAT), which sequesters target proteins into complexes formed by multimeric proteins and a blue light-mediated heterodimerization module. Using LARIAT, we inhibited diverse proteins that modulate cytoskeleton, lipid signaling and cell cycle with high spatiotemporal resolution. Use of single-domain antibodies extends the method to target proteins containing specific epitopes, including GFP.
Indexed as
Identifiers
24793453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.